Importer of Controlled Substances; Notice of Application: Cerilliant Corporation, 57176-57177 [2013-22536]

Download as PDF 57176 Federal Register / Vol. 78, No. 180 / Tuesday, September 17, 2013 / Notices During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: https:// www.usdoj.gov/enrd/Consent_ Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $25.25 (25 cents per page reproduction cost) payable to the United States Treasury. Susan M. Akers, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2013–22567 Filed 9–16–13; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE tkelley on DSK3SPTVN1PROD with NOTICES Notice of Lodging of Proposed Consent Decree Under the Clean Water Act On September 9, 2013, the Department of Justice lodged a proposed consent decree with the United States District Court for the District of South Carolina in the lawsuit entitled United States and State of South Carolina v. City of Columbia, Civil Action No. 3:13– 2429–TLW. The consent decree resolves allegations by the United States Environmental Protection Agency and the South Carolina Department of Health and Environmental Control against the City of Columbia (‘‘Columbia’’), in a complaint filed together with the consent decree, of violations of Sections 301 and 402 of the Clean Water Act, 33 U.S.C. 1311 and 1342, and Sections 48–1–50 and 48–1– 90(A)(1) of the South Carolina Pollution Control Act, at Columbia’s sanitary sewer system and wastewater treatment plant. Under this settlement between the United States, the State, and Columbia, Columbia is required to implement programs for sewer management, operation and maintenance, including: a sewer overflow response plan, a contingency emergency response plan, a staff training program, an information management system, a capacity assurance program to address insufficient capacity areas during peak flow times, a sewer mapping program, a fats, oils, and grease management program, a transmission system operation and maintenance program, a gravity sewer system operation and VerDate Mar<15>2010 17:05 Sep 16, 2013 Jkt 229001 maintenance program, and a financial analysis program to plan for sewer expenditures and upgrades. Columbia will also complete several capital improvement projects already underway and will implement a comprehensive sewer assessment program to analyze its sanitary sewer system infrastructure and prioritize infrastructure projects. It will then undertake infrastructure rehabilitation, along with developing a hydraulic model of the system to plan for future needs. The consent decree also provides for the payment of a civil penalty of $476,400, to be divided evenly between the United States and the State. Additionally, Columbia will spend $1.0 million on a Supplemental Environmental Project (‘‘SEP’’) to restore segments of three streams within the sewer system’s service area: the lower reach of Rocky Branch; a segment of Smith Branch; and a segment of Gills Creek. The publication of this notice opens a period for public comment on the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States v. City of Columbia, D.J. Ref. No. 90–5–1–1–09954. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By email ....... pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, D.C. 20044–7611 By mail ......... During the public comment period, the consent decree may be examined and downloaded at this Department of Justice Web site: https://www.usdoj.gov/ enrd/Consent_Decrees.html. We will provide a paper copy of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ— ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $26.00 (25 cents per page reproduction cost) for the consent decree alone or $56.25 for the consent PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 decree and appendixes, payable to the U.S. Treasury. Henry Friedman, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2013–22589 Filed 9–16–13; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application: Cerilliant Corporation Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on July 16, 2013, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances: Drug Cathinone (1235) .......................... Methcathinone (1237) .................. Mephedrone (1248) ...................... N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) Fenethylline (1503) ....................... Gamma Hydroxybutyric Acid (2010). JWH-018 (7118) ........................... JWH-073 (7173) ........................... JWH-200 (7200) ........................... Alpha-ethyltryptamine (7249) ....... Ibogaine (7260) ............................ CP-47497 (7297) .......................... CP-47497 C8 Homologue (7298) Lysergic acid diethylamide (7315) 2C-T-7 (7348) ............................... Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5-Trimethoxyamphetamine (7390). 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). 4-Methoxyamphetamine (7411) ... 5-Methoxy-N-Ndimethyltryptamine (7431). Alpha-methyltryptamine (7432) .... Diethyltryptamine (7434) .............. E:\FR\FM\17SEN1.SGM 17SEN1 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Federal Register / Vol. 78, No. 180 / Tuesday, September 17, 2013 / Notices Drug Schedule tkelley on DSK3SPTVN1PROD with NOTICES Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5-Methoxy-N,Ndiisopropyltryptamine (7439). N-Benzylpiperazine (7493) ........... MDPV (7535) ................................ Methylone (7540) ......................... Desomorphine (9055) ................... Etorphine (except HCl) (9056) ..... Heroin (9200) ............................... Morphine-N-oxide (9307) ............. Normorphine (9313) ..................... Pholcodine (9314) ........................ Dextromoramide (9613) ............... Dipipanone (9622) ........................ Racemoramide (9645) .................. Trimeperidine (9646) .................... 1-Methyl-4-phenyl-4propionoxypiperidine (9661). Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phencyclidine (7471) .................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Ethylmorphine (9190) ................... Meperidine (9230) ........................ Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Poppy Straw Concentrate (9670) Alfentanil (9737) ........................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II Dated: September 9, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. II II II II II II II II II [FR Doc. 2013–22536 Filed 9–16–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Office of Justice Programs [OJP (OJP) Docket No. 1631] The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards. In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration. Comments and requests for hearing on applications to import narcotic raw material are not appropriate. 72 FR 3417 (2007). Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the circumstances set VerDate Mar<15>2010 17:05 Sep 16, 2013 Jkt 229001 forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 17, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Meeting of the Office of Justice Programs’ Science Advisory Board Office of Justice Programs (OJP), Justice. ACTION: Notice of meeting. AGENCY: This notice announces a forthcoming meeting of OJP’s Science Advisory Board (‘‘Board’’). The Board is chartered to provide OJP, a component of the Department of Justice, with valuable advice in the areas of science and statistics for the purpose of enhancing the overall impact and performance of its programs and activities in criminal and juvenile justice. To this end, the Board has designated six (6) subcommittees: National Institute of Justice (NIJ); Bureau of Justice Statistics (BJS); Office of Juvenile Justice and Delinquency SUMMARY: PO 00000 Frm 00051 Fmt 4703 Sfmt 9990 57177 Prevention (OJJDP); Bureau of Justice Assistance; Quality and Protection of Science; and Evidence Translation/ Integration. The meeting will take place on Friday, October 4, 2013, from 8:30 a.m. to 4:00 p.m., ET, with a break for lunch at approximately noon. DATES: The meeting will take place in the Main Conference Room on the third floor of the Office of Justice Programs, 810 7th Street, Northwest, Washington, DC 20531. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Phelan Wyrick, Designated Federal Officer (‘‘DFO’’), Office of the Assistant Attorney General, Office of Justice Programs, 810 7th Street Northwest, Washington, DC 20531; Phone: (202) 353–9254 [Note: this is not a toll-free number]; Email: phelan.wyric@ usdoj.gov. This meeting is being convened to brief the OJP Assistant Attorney General and the Board members on the progress of the subcommittees, discuss any recommendations they may have for consideration by the full Board, and brief the Board on various OJP-related projects and activities. The final agenda is subject to adjustment, but it is anticipated that there will be a morning session and an afternoon session, with a break for lunch. These sessions will likely include briefings of the subcommittees’ activities and discussion of future Board actions and priorities. This meeting is open to the public. Members of the public who wish to attend this meeting must register with Phelan Wyrick at the above address at least seven (7) days in advance of the meeting. Registrations will be accepted on a space available basis. Access to the meeting will not be allowed without registration. Persons interested in communicating with the Board should submit their written comments to the DFO, as the time available will not allow the public to directly address the Board at the meeting. Anyone requiring special accommodations should notify Mr. Wyrick at least seven (7) days in advance of the meeting. SUPPLEMENTARY INFORMATION: Phelan Wyrick, Science Policy Advisor and Science Advisory Board DFO, Office of the Assistant Attorney General, Office of Justice Programs. [FR Doc. 2013–22628 Filed 9–16–13; 8:45 am] BILLING CODE 4410–18–P E:\FR\FM\17SEN1.SGM 17SEN1

Agencies

[Federal Register Volume 78, Number 180 (Tuesday, September 17, 2013)]
[Notices]
[Pages 57176-57177]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-22536]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application: 
Cerilliant Corporation

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on July 16, 2013, Cerilliant Corporation, 811 Paloma 
Drive, Suite A, Round Rock, Texas 78665-2402, made application by 
renewal to the Drug Enforcement Administration (DEA) for registration 
as an importer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
Mephedrone (1248)..........................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
Fenethylline (1503)........................  I
Gamma Hydroxybutyric Acid (2010)...........  I
JWH-018 (7118).............................  I
JWH-073 (7173).............................  I
JWH-200 (7200).............................  I
Alpha-ethyltryptamine (7249)...............  I
Ibogaine (7260)............................  I
CP-47497 (7297)............................  I
CP-47497 C8 Homologue (7298)...............  I
Lysergic acid diethylamide (7315)..........  I
2C-T-7 (7348)..............................  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
5-Methoxy-N-N-dimethyltryptamine (7431)....  I
Alpha-methyltryptamine (7432)..............  I
Diethyltryptamine (7434)...................  I

[[Page 57177]]

 
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
N-Benzylpiperazine (7493)..................  I
MDPV (7535)................................  I
Methylone (7540)...........................  I
Desomorphine (9055)........................  I
Etorphine (except HCl) (9056)..............  I
Heroin (9200)..............................  I
Morphine-N-oxide (9307)....................  I
Normorphine (9313).........................  I
Pholcodine (9314)..........................  I
Dextromoramide (9613)......................  I
Dipipanone (9622)..........................  I
Racemoramide (9645)........................  I
Trimeperidine (9646).......................  I
1-Methyl-4-phenyl-4-propionoxypiperidine     I
 (9661).
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Ethylmorphine (9190).......................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Thebaine (9333)............................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Poppy Straw Concentrate (9670).............  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to import small quantities of the listed 
controlled substances for the manufacture of analytical reference 
standards.
    In reference to drug codes 7360 and 7370, the company plans to 
import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No 
other activity for this drug code is authorized for this registration.
    Comments and requests for hearing on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (2007).
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedules I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 17, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substances 
in schedules I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: September 9, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-22536 Filed 9-16-13; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.